ibrutinib for cll within a population-based setting: a promising outlook
Published 6 years ago • 150 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:07
ibrutinib treatment for cll yields different pfs in population-based setting
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
2:00
population-based studies for ibrutinib in cll
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
6:48
patient selection for treatment with ibrutinib in cll
-
3:24
preventing ibrutinib flare in cll
-
2:13
major breakthroughs in the field of bpdcn: combination therapies, managing cns involvement & more
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
2:00
ibrutinib: use in small cll subgroups only?
-
1:56
ibrutinib treatment and its associated risk factors
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
1:56
emerging ibrutinib-based combinations in cll